This is good - IP will come out of it - Then M&A MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates
- MediPharm Labs’ Cannabis Drug Licence and expertise
- ---> qualifies and positions the Company to supply clinical trial material,
- --->assist in investigation protocol and provide regulatory support for multiple trials
-
- Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indications
- -->including Pain,
- -->Insomnia associated with Major Depression, and
- -->Uremic Pruritus.
BARRIE, Ontario, June 21, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. .... is pleased to announce it has entered into a research partnership Master Agreement (the “Agreement”) with McMaster University.
-->The Agreement is a key step that enables MediPharm Labs to work with McMaster University’s large and diversified roster of
-->clinicians leading the way in cannabis research and drug development.
Under the terms of the Agreement, MediPharm Labs will enter into a separate Statement of Work with each clinician group.
MediPharm Labs will use its Cannabis Drug Licence to provide access to clinical trial material that meets pharmaceutical quality standards and Good Manufacturing Practice (GMP), as well as investigative protocol and regulatory approval support.
MediPharm Labs and McMaster University researchers have proposed three distinct clinical trials, each led by separate clinician groups looking to develop novel cannabis-based drugs to treat different indications including pain, insomnia associated with major depression, and uremic pruritus.
MediPharm Labs will assist in the development of the study drugs that will be evaluated, and each will name a Principal Investigator physician.
MediPharm Labs’ expertise in formulation and delivery methods will be critical to the execution of these trials. Before each study begins, all necessary approvals from relevant regulatory authorities, including Health Canada, will be obtained.
“As a pharmaceutical company specialized in cannabis, MediPharm Labs is excited to participate in the development of drugs containing cannabis. This will further our initiative to fulfill the global need for pharmaceutically approved drugs containing cannabis. We are honoured to partner with McMaster University, a global leader in medical cannabis research.” said Keith Strachan, President and Interim CEO, MediPharm Labs.
The Company looks forward to further announcements regarding specific projects under the Agreement as the projects receive initial Health Canada support.